BlackRock and Wentworth Capital have acquired two life sciences facilities as seed assets for a new A$1.5bn (€907m) Australian life sciences real estate platform. The acquired assets comprise a Red ...

Gilead Sciences (GILD) closed the most recent trading day at $88.82, moving +0.6% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 1.86% for the day.

As you get closer, the image becomes clear and you unconsciously hold your breath. It’s a black cat out for its morning stroll. You pause for a second to decide your next move. Cross the street ...

STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

This Is Lorelei, Black Country New Road, Cassandra Jenkins, and many more. It’s also the first-announced Europe show for the newly-reunited Cap’n Jazz, whose booking agent recently teased a ...

Gilead Sciences (GILD) closed the latest trading day at $87.23, indicating a -1.05% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.92%. Meanwhile ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price target at $84.00. Terence Flynn’s rating is based on ...

The treatment combines MSD’s islatravir with Gilead’s lenacapavir. Credit: Ground Picture via Shutterstock. Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II ...